Brokers Issue Forecasts for NextCure FY2029 Earnings

NextCure, Inc. (NASDAQ:NXTC) – Equities researchers at HC Wainwright issued their FY2029 earnings estimates for NextCure in a research report issued to clients and investors on Friday, March 7th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.55) for the year. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for NextCure’s current full-year earnings is ($1.87) per share.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07).

NextCure Stock Up 5.2 %

NXTC opened at $0.75 on Monday. The firm has a market cap of $21.01 million, a price-to-earnings ratio of -0.36 and a beta of 0.71. NextCure has a fifty-two week low of $0.66 and a fifty-two week high of $2.57. The company’s 50-day moving average price is $0.78 and its 200 day moving average price is $1.12.

Institutional Investors Weigh In On NextCure

Several institutional investors and hedge funds have recently bought and sold shares of the business. Tang Capital Management LLC raised its stake in NextCure by 7.3% during the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock worth $540,000 after acquiring an additional 47,614 shares during the period. Citadel Advisors LLC increased its stake in shares of NextCure by 40.6% in the fourth quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock valued at $61,000 after purchasing an additional 22,724 shares during the period. Renaissance Technologies LLC increased its stake in shares of NextCure by 27.9% in the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock valued at $400,000 after purchasing an additional 113,300 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of NextCure in the fourth quarter valued at approximately $311,000. Finally, Geode Capital Management LLC increased its stake in shares of NextCure by 14.2% in the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after purchasing an additional 27,812 shares during the period. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.